19th Feb 2016 07:05
LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Friday said the European Commission has granted its Zurampic product authorisation for gout treatment in the European Union.
The EC has approved the drug in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia in adult in adults with gout.
"There has been limited therapy innovation in gout over the last 50 years. With the approval of Zurampic, we are pleased to offer a new treatment option for the many patients who are suffering from the effects of gout and who are not reaching the recommended serum uric acid treatment targets with the current standard of care," said Sean Bohen, vice-president of global medicines development and chief medical officer at the FTSE 100-listed group.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca